About this trial
Lower respiratory tract infections (LRTIs) remain a major global health burden, with diagnosis often challenged by clinical heterogeneity, overlapping symptoms, difficulty in obtaining quality biological specimens and limitations of conventional microbiological testing. Exhaled breath contains thousands of volatile organic compounds (VOCs), arising from both host metabolism and microbial activity, and provides a non-invasive window into the metabolic landscape of infection. Emerging evidence from in vitro studies, animal models, and clinical investigations supports the existence of pathogen-specific VOC signatures. However, most published studies have relied on offline methods, such as gas chromatography-mass spectrometry (GC-MS), and robust proof-of-concept for real-time, bedside analysis in diverse, real-world populations is lacking. Proton transfer reaction-mass spectrometry (PTR-MS) offers rapid, quantitative, and non-invasive assessment of breath VOCs in both spontaneously breathing and mechanically ventilated patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient aged > 1 month, either spontaneously breathing or intubated and mechanically ventilated
Having suspected lower respiratory tract infection (dyspnea or tachypnea or cough or sputum production or fever or decreased breath sounds on auscultation or any other suspicious diagnostic test (imaging, blood analysis)) or previously documented chronic airway colonization
Willing to provide informed consent and affiliated with a health insurance system
Disqualifiers
Patients or representative unable to provide informed consent
Persons under guardianship or curatorship or persons deprived of liberty
Trial design
Single group
Treatments tested in this trial
Breath analysis
Diagnostic testbreath sampling and collection and analysis (microscopic analysis, cultures and syndromic panel of a respiratory sample
Treatment groups
Trial outcomes
Primary outcomes
Infection test
Breath VOC signature for patient categorical classification of LRTI (infection / colonization / none)
Secondary outcomes
Pathogen class test
Breath VOC signature differentiating bacterial and viral infections
Pathogen ID test
Breath VOC signature differentiating major respiratory pathogens
Diagnostic performance
Sensitivity, specificity, negative predictive value, positive predictive value, area under the ROC curve, accuracy of each test compared to reference standards
Antimicrobial susceptibility test
Breath VOC signature differentiating susceptibility and resistance of a given pathogen to a given antibiotic (exploratory outcome).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: